Publications

John Schmitz, PhD

Bakkenist CJ, Czambel RK, Lin Y, Yates NA, Zeng X, Shogan J, Schmitz JC. Quantitative analysis of ATM phosphorylation in lymphocytes. DNA Repair (Amst). 2019 Jun 4;801-7. doi: 10.1016/j.dnarep.2019.06.002. PubMed PMID: 31176958.
Omana-Zapata I, Mutschmann C, Schmitz J, Gibson S, Judge K, Aruda Indig M, Lu B, Taufman D, Sanfilippo AM, Shallenberger W, Graminske S, McLean R, Hsen RI, d'Empaire N, Dean K, O'Gorman M. Accurate and reproducible enumeration of T-, B-, and NK lymphocytes using the BD FACSLyric 10-color system: A multisite clinical evaluation. PLoS One. 2019;14(1):e0211207. doi: 10.1371/journal.pone.0211207. PubMed PMID: 30689658; PMCID: PMC6349332.
Wei N, Li J, Fang C, Chang J, Xirou V, Syrigos NK, Marks BJ, Chu E, Schmitz JC. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. Oncogene. 2019 Mar;38(10):1676-1687. doi: 10.1038/s41388-018-0547-y. PubMed PMID: 30348989.
Bakkenist CJ, Lee JJ, Schmitz JC. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17(4):255-257. doi: 10.1016/j.clcc.2018.09.001. PubMed PMID: 30316683; PMCID: PMC6561466.
Pal R, Wei N, Song N, Wu S, Kim RS, Wang Y, Gavin PG, Lucas PC, Srinivasan A, Allegra CJ, Jacobs SA, Paik S, Schmitz JC, Pogue-Geile KL. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PLoS One. 2018;13(8):e0200836. doi: 10.1371/journal.pone.0200836. PubMed PMID: 30118499; PMCID: PMC6097647.
Liu H, Liu H, Zhou Z, Parise RA, Chu E, Schmitz JC. Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway. Cell Commun Signal. 2018 Feb 20;16(1):7. doi: 10.1186/s12964-018-0218-1. PubMed PMID: 29458395; PMCID: PMC5819251.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. PubMed PMID: 28770300; PMCID: PMC5734661.
Ferry-Galow KV, Ji J, Kinders RJ, Zhang Y, Czambel RK, Schmitz JC, Herzog J, Evrard YA, Parchment RE. Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay. Semin Oncol. 2016 Aug;43(4):492-500. doi: 10.1053/j.seminoncol.2016.06.007. PubMed PMID: 27663481.
Bakkenist CJ, Beumer JH, Schmitz JC. ATM serine-1981 phosphorylation is a plausible biomarker. Cell Cycle. 2015;14(20):3207-8. doi: 10.1080/15384101.2015.1084205. PubMed PMID: 26517194; PMCID: PMC4825586.
Wu S, Guo Z, Hopkins CD, Wei N, Chu E, Wipf P, Schmitz JC. Bis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells. Oncotarget. 2015 Dec 1;6(38):40866-79. doi: 10.18632/oncotarget.5885. PubMed PMID: 26506423; PMCID: PMC4747374.
Bakkenist CJ, Czambel RK, Hershberger PA, Tawbi H, Beumer JH, Schmitz JC. A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. Oncoscience. 2015;2(5):542-54. doi: 10.18632/oncoscience.162. PubMed PMID: 26097887; PMCID: PMC4468340.

<< Investigators Search

Top